jam-packed week full of genius startups
Alan raises $220 million for its health insurance and healthcare superapp
French startup Alan has raised a $220 million funding round at a $1.67 billion valuation (€185 million and €1.4 billion respectively). Coatue is leading the round with Dragoneer, Exor, and existing investors Index Ventures, Ribbit Capital and Temasek also participating. With today’s funding round, the company can iterate on its core product — health insurance — and everything that makes Alan a superapp — a single app that lets you access several services. In France, employees are covered by both the national healthcare system and private insurance companies. Alan sells its products to other companies so that their employees are automatically covered by Alan contracts. It’s a sort of B2B2C play. 9,400 companies have opted for Alan in France, Belgium and Spain — the company’s home market remains its main market. Clients include WeWork, Deliveroo, JustEat, Vitaliance and Big Mamma. By 2023, Alan wants to reach 1 million members. In order to gain more customers, Alan is betting on three pillars — product innovation, customer satisfaction through additional services, and expansions to new verticals and markets. Alan managed to meet its goals and international expansion finally started to take off.
https://finance.yahoo.com/news/alan-raises-220-million-health-153000952.htmlLumicks Raises $93M in Series D Financing
Lumicks, an Amsterdam, The Netherlands-based life science tools company that develops innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, closed a $93m Series D funding.
The round was led by new investors Farallon Capital Management and Lauxera Capital Partners, with participation from Softbank Vision 2, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Pura Vida Investments, and Irving Investors, as well as existing investor Gilde Healthcare and select members of the management team.
The company intends to use the funds to accelerate growth initiatives including expansion of both research and development and commercial activities for the z-Movi® Cell Avidity Analyzer.
Founded in 2014 as an academic spin-off from the research group of Prof. Gijs Wuite, Prof. Erwin Peterman, and Prof. Iddo Heller at the Vrije Universiteit Amsterdam, and led by Olivier Heyning, CEO, Lumicks is a life science tools company that develops equipment for Dynamic Single-Molecule and Cell Avidity analysis, two emerging areas in biology research and immuno-oncology. Built upon innovative technologies, such as optical tweezers (Nobel Prize for Physics 2018) and STED super-resolution (Nobel Prize for Chemistry 2014), the company’s tools facilitate the understanding of life to the smallest detail.
Lumicks Raises $93M in Series D Financing | FinSMEs
Lumicks, an Amsterdam, The Netherlands-based life science tools company that develops innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, closed a $93m Series D funding
Alchemab Therapeutics Raises £60M in Series A Financing
Alchemab Therapeutics, a Cambridge, England, UK-based biotech company developing novel products for patients with diseases by harnessing naturally protective antibodies, completed a £60m ($82m) Series A financing round.
The round was led by RA Capital Management, with participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund.
The company, which was created by SV Health Investors who led the Seed round in 2019, intends to use the advance its target-agnostic drug discovery platform.
Founded in 2019 and led by Alex Leech, CEO, and Dr Jane Osbourn OBE, CSO, Alchemab has developed a platform which enables the identification of novel drug targets and therapeutics on the basis of patient B-cell antibody repertoires. The platform uses defined patient samples and a range of functional and advanced analytical techniques to evaluate convergent protective antibody responses in groups of individuals that are susceptible but resilient to specific diseases.
Alchemab Therapeutics Raises £60M in Series A Financing
Alchemab Therapeutics, a Cambridge, England, UK-based biotech company developing novel products for patients with diseases by harnessing naturally protective antibodies, completed a £60m ($82m) Series A financing round
Oxford-based biotech Biomicrogel Group raises $13 million to save nature
Biomicrogels Group has raised $13 million in an effort to bring their products to the global market and save nature from pollution.
The round was led by Swiss Investor Gregory Berenstein.
Founded in 2015, Biomicrogel Group uses microgel technology from the medical and pharmaceutical industries and has created industrial and home cleaning products. On the industrial side, Biomicrogel cleans oil and petrol from wastewater, eliminates oil spills, and increases vegetable oil extraction. Notably, this past summer, Biomicrogel’s products were instrumental in helping to mitigate the diesel fuel spill accident in Norilsk.
On the consumer front, Biomicrogel Group’s WONDER LAB brand includes products for everyday home cleaning, laundry, and fruit and vegetable washing.
The products are made from plant raw materials, and the Group’s technology holds 80 patents in 62 countries.
Oxford-based biotech Biomicrogel Group raises $13 million to save nature – Tech.eu
Biomicrogels Group has raised $13 million in an effort to bring their products to the global market and save nature from pollution. The round was led by Swiss Investor Gregory […]
Imageens Raises €1.2M in Seed Financing
Imageens, a Paris, France-based medical Artificial Intelligence (AI) startup developing software solutions for the analysis of medical images, raised €1.2M in seed financing.
The round was led by Anaxago, with participation from BADGE (Business Angels des Grandes Ecoles), COALESCENCE, and existing investors.
Led by Robert Baldwin, CEO, Imageens provides software solutions that allow radiologists, cardiologists and vascular surgeons to make personalized decisions and to assess the cardiovascular risk of their patients, thanks to highly accurate medical imaging data.
The company intends to use the funds to accelerate the development and commercialization of ArtFun+, an artificial intelligence software and its prognostic biomarkers for cardiovascular imaging, and LABEL, an algorithmic solution for the automatic classification and valorization of medical imaging data, to strengthen its team with key R&D talents and build its commercial team to scale the deployment of its software solutions.
Imageens Raises €1.2M in Seed Financing | FinSMEs
Imageens, a Paris, France-based medical Artificial Intelligence (AI) startup developing software solutions for the analysis of medical images, raised €1.2M in seed financing
Adagio Therapeutics Raises $336M in Series C Financing
Adagio Therapeutics, Inc., a Waltham, Mass. – based biotechnology company developing antibodies to broadly neutralize coronaviruses, completed a $336m Series C financing.
The round was led by RA Capital Management, with participation from new investors, including Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another leading healthcare investor. Existing investors Fidelity Management & Research Company, LLC, OrbiMed, Polaris Partners, Mithril, GV, Population Health Partners, Adimab and Omega Funds.
The company intends to use the funds for continued advancement of ADG20, its lead clinical candidate being developed as a single agent for both the treatment and prevention of COVID-19, the disease caused by the virus SARS-CoV-2, as well potential future coronaviruses.
Led by Tillman Gerngross, Ph.D., Co-Founder & CEO, Adagio is developing antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV and additional pre-emergent coronaviruses. Its portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20.
Adagio Therapeutics Raises $336M in Series C Financing
Adagio Therapeutics, Inc., a Waltham, Mass. – based biotechnology company developing antibodies to broadly neutralize coronaviruses, completed a $336m Series C financing
Virta Health Raises $133M in Series E Funding
Virta Health, a San Francisco, CA-based type 2 diabetes reversal company, raised $133m in financing.
The round was led by Tiger Global.
The company intends to use the funds for research and product innovation, and increase of demand for diabetes reversal from employers, health plans, and government.
Led by Sami Inkinen, Co-founder and CEO, Virta Health provides a telehealth-powered diabetes reversal treatment for people to reverse type 2 diabetes and other chronic conditions. The company reverses type 2 diabetes through innovations in technology, nutrition science, and continuous remote care from physicians and behavioral experts. Virta works with with over 100 organizations, including the largest health plans, employers, and government and treats patients in all 50 states.
Virta Health Raises $133M in Series E Funding | FinSMEs
Virta Health, a San Francisco, CA-based type 2 diabetes reversal company, raised $133m in financing
Arcellx Raises $115M in Series C Financing
Arcellx, a Gaithersburg, Md.-based clinical-stage biopharmaceutical company advancing a pipeline of adaptive and controllable cell therapies, raised $115m in Series C financing.
The round was co-led by Samsara BioCapital and CAM Capital, joined by new investors Adage, Asymmetry, CaaS Capital, Cambrian Bio, Sixty Degree, Soleus Capital, Surveyor Capital (a Citadel company), Suvretta, and Terra Magnum Capital Partners, and existing investors NEA, Novo Holdings, SR One, Takeda Ventures, LG Tech, and Clough Capital.
The company intends to use the funds to develop CART-ddBCMA, a BCMA-specific CAR-modified T-cell therapy currently in Phase 1 and anticipated to begin a pivotal trial in 2022, and initiate clinical trials evaluating ACLX-001 and ACLX-002, cell therapies derived from its controllable ARC-SparX platform, in multiple myeloma (MM) and acute myelogenous leukemia (AML), respectively.
Led by Rami Elghandour, Chairman and Chief Executive Officer, Arcellx is a clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases.
Arcellx Raises $115M in Series C Financing | FinSMEs
Arcellx, a Gaithersburg, Md.-based clinical-stage biopharmaceutical company advancing a pipeline of adaptive and controllable cell therapies, raised $115m in Series C financing
C2i Genomics Raises $100M in Funding
C2i Genomics, a New York, NY-based cancer intelligence company, raised $100m in financing.
The round was led by Casdin Capital with participation from NFX, Duquesne Family Office, Section 32, iGlobe Partners, Driehaus Capital and others. The financing was executed as a convertible note with two tranches of $50m, called by the company with additional participation from The Mark Foundation for Cancer Research, Silver Lake, Alexandria Real Estate, Gordon Asset Management, and LionBird.
The company intends to use the funds to accelerate clinical development and commercialization of its C2-Intelligence Platform and to deepen its partnerships with pharmaceutical companies.
Led by Asaf Zviran, co-founder and CEO, C2i provides a cloud-based cancer diagnostics service that uses AI pattern recognition and whole-genome analysis to provide rapid and accurate detection of residual disease. With the platform, physicians can spot trace amounts of persistent or recurrent cancer much earlier, at far lower levels, to inform treatment decisions. The technology can be deployed locally to provide actionable insights into the progression of a patient’s cancer as rapidly as in one week, enabling informed and timely treatment decisions.
C2i Genomics Raises $100M in Funding | FinSMEs
C2i Genomics, a New York, NY-based cancer intelligence company, raised $100m in financing
Theseus Pharmaceuticals Raises $100M in Series B Funding
Theseus Pharmaceuticals, a Boston, MA-based biotechnology company focused on oncology by developing pan-variant kinase inhibitors, emerged from stealth with the close of a $100m Series B financing.
The round was led by Foresite Capital with participation from Adage Capital Management, Boxer Capital, Farallon Capital Management, Longitude Capital, Nextech Ventures, Omega Healthcare Investors, Pontifax Venture Capital, Rock Springs Capital, and T. Rowe Price, as well as OrbiMed. In conjunction with the financing, Michael Rome, Ph.D., Managing Director of Foresite Capital, has joined the Theseus Board of Directors, which also includes Carl Gordon, General Partner at OrbiMed.
Theseus Pharmaceuticals is developing a pipeline of pan-variant tyrosine kinase inhibitors (TKIs) that can anticipate and inhibit new cancer mutations. The company’s lead candidate, THE-630, is a next-generation pan-variant KIT inhibitor in development for the treatment of refractory GIST. Theseus expects to file an IND before the end of the year.
The pipeline also includes a selective EGFR inhibitor to overcome C797S-mediated resistance to first- or later-line osimertinib treatment for patients with non-small cell lung cancer, and a third kinase target candidate for an undisclosed indication.
The company is led by William C. Shakespeare, Ph.D., Co-founder and President of Research and Development, and Iain Dukes, D. Phil., Co-founder and Interim CEO.
Theseus Pharmaceuticals Raises $100M in Series B Funding | FinSMEs
Theseus Pharmaceuticals, a Boston, MA-based biotechnology company focused on oncology by developing pan-variant kinase inhibitors, emerged from stealth with the close of a $100m Series B financing
TetraScience raises $80M to help life sciences companies analyze data
TetraScience, an R&D cloud data management company focused on life sciences and drug discovery, today announced that it raised $80 million in a series B round co-led by Insight Partners and Alkeon Capital. The company says that the funding will allow it to ramp up its go-to-market efforts, expand its technical capabilities, and double the size of its team.
TetraScience, which was founded by former Harvard and MIT researchers, offers cloud storage, an API, and prebuilt integrations with lab instruments, informatics applications, analytics, and data science partners that pull in and reconcile data. TetraScience can automatically harmonize information across vendors and formats and enable users to share data, reports, analyses, and apps with internal teams.
TetraScience raises $80M to help life sciences companies analyze data | VentureBeat
TetraScience, a startup building cloud tools for managing and analyzing life sciences data, has raised $80 million.
Atlast Raises $40M in Series A Funding
Atlast Food Co., a Green Island, N.Y.-based mycelium food company making plant-based meats, raised $40M in Series A funding.
The round was led by Viking Global Investors with participation from 40 North, AiiM Partners, Senator Investment Group, Stray Dog Capital, Footprint Coalition Ventures, and the leaders and founders of food and CPG companies, including Applegate, Stonyfield, and Whole Foods.
The company intends to use the funds to further develop and scale this technology and team.
Led by Stephen Lomnes, President, Atlast Food is an American food technology company. Its patented platform uses a natural super ingredient called mycelium to grow nutrient-rich fibers that replicate the textures and mouthfeel of meat for CPG partners. MyEats is a direct-to-consumer food brand currently selling MyBacon™ strips throughout the U.S. MyEats’ first product is a plant-based bacon that offers all the taste, crunch and sizzle of pork bacon, but is made from just six ingredients.
Atlast Raises $40M in Series A Funding | FinSMEs
Atlast Food Co., a Green Island, N.Y.-based mycelium food company making plant-based meats, raised $40M in Series A funding
Cohere Health Raises Additional $36M in Series B Funding
Cohere Health, a Boston, MA-based digital health company, closed a $36m Series B funding.
The round was led by Polaris Partners, with participation from new investors Longitude Capital and Deerfield Management, as well as existing investors Flare Capital Partners and Define Ventures.
The company intends to use the funds to continue enhancement of its digital health plan solutions.
Led by Siva Namasivayam, CEO, Cohere Health provides digital health plan solutions to drive collaborative care journeys. The company’s solutions automate provider and payer preauthorization functions and generate clinical policy guidance that drives care decisions without having to delay or deny care. Cohere then uses prior authorization as a trigger to engage plans, providers and patients in episode-based care paths that merge traditional utilization management, care management and patient engagement functions to ensure plan benefits are fully utilized. The company works with physicians and health plans.
Cohere Health Raises Additional $36M in Series B Funding | FinSMEs
Cohere Health, a Boston, MA-based digital health company, closed a $36m Series B funding
Hungry Planet Raises $25M Series A Financing Round
Hungry Planet, Inc., a St. Louis, Missouri-based plant-based meat company, closed a $25m Series A financing round.
Post Holdings (NYSE: POST) led the round, joined by Singaporean investment group TRIREC, and included other plant-forward investors.
The company intends to use the funds to build capacity for its plant-based meats, and accelerate growth across retail, foodservice and e-commerce channels, both domestically and internationally.
Co-founded by Todd Boyman, CEO, and Jody Boyman, Hungry Planet offers a large range of chef-crafted meats that match traditional meat textures and tastes with non-GMO plant-based ingredients.
Hungry Planet Raises $25M Series A Financing Round | FinSMEs
Hungry Planet, Inc., a St. Louis, Missouri-based plant-based meat company, closed a $25m Series A financing round
Tomorrow Health Raises $25M in Series A Financing
Tomorrow Health, a NYC-based patient-first platform for home healthcare, closed a $25m Series A funding round.
The round was led by Andreessen Horowitz with participation from Obvious Ventures and BoxGroup. Julie Yoo, General Partner at Andreessen Horowitz, is joining the company’s board.
The company will use the capital to hire additional talent and expand its infrastructure technology to connect every patient with home-based care.
Led by Vijay Kedar, co-founder and Chief Executive Officer, Tomorrow Health provides a platform for home healthcare that enables patients to get the equipment and supplies they require in a streamlined manner. Partnering with payors, referring providers, and DME suppliers, the company provides a data-driven intelligence platform to match patients with high-quality DME suppliers based on insurance coverage, service quality, geography, and product specialization.
Tomorrow Health Raises $25M in Series A Financing | FinSMEs
Tomorrow Health, a NYC-based patient-first platform for home healthcare, closed a $25m Series A funding round
Multiply Labs Raises $20M in Series A Funding
Multiply Labs, a San Francisco, CA-based robotics company developing automated manufacturing systems for the production of individualized drugs, raised $20m in Series A financing.
The round, which brought total funding raised to date to more than $25m, was led by Casdin Capital with participation from new investors Lux Capital and Pathfinder, Founders Fund’s early stage investment vehicle, Fifty Years and Garage Capital. In conjunction with the funding, Michael Doherty, a representative of Casdin Capital, will join Multiply Labs’ Board of Directors.
The company intends to use the funds to grow its installed robotic production capacity, and to apply its tech to new life-saving therapies.
Led by Fred Parietti, PhD, Co-founder and CEO, Multiply Labs is developing cloud-controlled robotic systems for the production of experimental cell therapies in collaboration with a Consortium of industrial and research organizations in the space.
Multiply Labs Raises $20M in Series A Funding | FinSMEs
Multiply Labs, a San Francisco, CA-based robotics company developing automated manufacturing systems for the production of individualized drugs, raised $20m in Series A financing
ImmunoScape Raises $14M in Funding
ImmunoScape, a Singapore and San Diego, CA-based biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, completed a $14m funding round.
The round, which brought total funding to $25m, was led by existing investors Anzu Partners, University of Tokyo Edge Capital Partners (UTEC) and new investor EDBI, an investment arm of the Economic Development Board of Singapore.
The company intends to use the funds to enlarge its team, further its expansion into the U.S., scale up its newly announced San Diego laboratory, and continue advancing the capabilities of its Deep Immunomics platform that enables the characterization of a patient’s immunome at ultra-high resolution.
Led by Choon Peng Ng, CEO, ImmunoScape provides a Deep Immunomics platform that integrates single-cell analysis technologies and bioinformatics for both drug discovery and high-dimensional immune profiling.
ImmunoScape Raises $14M in Funding | FinSMEs
ImmunoScape, a Singapore and San Diego, CA-based biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, completed a $14m funding round
Encamp Raises $12M in Series B Funding
Encamp, an Indianapolis, IN-based company which provides a software platform for environmental, health, and safety (EHS) compliance data management and reporting automation, raised $12m in Series B funding.
The round was led by OpenView with participation from High Alpha Capital, Allos Ventures, and IU Ventures.
The company will use the funds for ongoing development of the SaaS-based Encamp platform and add employees in engineering, compliance, sales, marketing, and other strategic areas.
Led by Luke Jacobs, co-founders and CEO, Gerritt Graham, Chief Revenue Officer, Julianna Meidell, VP of Marketing, and Ki Moon, VP of Revenue Operations, Encamp provides a SaaS-based software platform for the environmental, health, and safety (EHS) industry.
Encamp Raises $12M in Series B Funding | FinSMEs
Encamp, an Indianapolis, IN-based company which provides a software platform for environmental, health, and safety (EHS) compliance data management and reporting automation, raised $12m in Series B funding
South African e-health startup Quro Medical is emerging from stealth mode to announce the closure of a seven-figure US dollar seed funding round to accelerate growth.
Founded in 2018, Quro Medical has developed an affordable and accessible hospital-at-home solution that combines state-of-the-art hardware and software with clinical excellence to manage acutely ill patients in the comfort of their homes.
The startup is building the largest virtual hospital ward in Africa, which seeks to achieve superior clinical outcomes to conventional care at a lower cost. Quro Medical’s platform reduces the costs of healthcare delivery by leveraging real-time, data-driven clinical interventions.
It has now secured an undisclosed seven-figure seed investment, with the round led by Enza Capital and Mohau Equity Partners. Quro Medical will use the funding to scale its operations across South Africa to meet the demands of its growing client base, attract and retain talent and extend into markets with a highly competitive and innovative offering in a sector that is ripe and ready for innovation.
SA e-health startup Quro Medical raises 7-figure seed round to accelerate growth - Disrupt Africa
South African e-health startup Quro Medical is emerging from stealth mode to announce the closure of a seven-figure US dollar seed funding round to accelerate growth.
Thermo Fisher acquires PPD for $ 21 billion
The US laboratory equipment supplier buys after the failed takeover of Qiagen in the home market. Thermo Fisher takes on billions in debt. With the acquisition, the group wants to expand its business as a service provider for clinical research. In addition to the purchase price of $ 17.4 billion, Thermo Fisher also has to finance $ 3.5 billion in debt from PPD.
Biotechbranche: Thermo Fisher übernimmt PPD für 21 Milliarden Dollar
Der US-Laborausrüster kauft nach der gescheiterten Übernahme von Qiagen im Heimatmarkt zu. Thermo Fisher übernimmt dafür Schulden in Milliardenhöhe.
Cork’s Healthcare 21 snapped up by Swedish firm in €245m deal
AddLife is acquiring the Irish business as part of its continued expansion in the European life sciences sector.
Cork-headquartered Healthcare 21, which provides distribution and services to healthcare organisations, is being acquired in a deal worth up to €245m. Healthcare 21 supplies medical equipment such as ventilators, beds and blood pressure monitoring equipment from its warehouse in Blarney, Co Cork. It works with medical facilities and organisations including the HSE in Ireland and the NHS in the UK.
The company was founded in 2003 by Owen Curtin, who recently told Siliconrepublic.com about the challenges of supplying healthcare equipment during the pandemic.
Cork’s Healthcare 21 snapped up by Swedish firm in €245m deal
AddLife is acquiring Irish business Healthcare 21 as part of its continued expansion in the European life sciences sector.
NaviMed Capital Closes Second Fund, at $290M
NaviMed Capital, a Washington, DC area-based healthcare focused private equity firm, closed its second fund, NaviMed Partners II, at $290m.
Co-founded by Managing Directors Brian Canann, Dr. Bijan Salehizadeh and Ryan Schwarz, NaviMed will continue to focus on control investments in fast growing lower middle-market healthcare services, healthcare IT, hospital products, and pharmaceutical services businesses.
